Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Oral Prednisolone Dosing in Children Hospitalized With Asthma

23 de diciembre de 2010 actualizado por: Children's Hospital of Philadelphia
This study hopes to determine the appropriate oral steroid dose for treating children hospitalized with asthma exacerbations. Practice guidelines from different countries recommend a wide range of doses, and the doses used in actual practice vary widely. There is no data on what is the most appropriate dose of prednisone (or equivalent) in this situation. We will be looking at the dose recommended by the National Asthma Education and Prevention Program guidelines, which are published by the National Heart, Lung, and Blood Institute, as compared with a lower dose which is commonly used in practice. We hypothesize that the lower dose will be no worse than the higher dose as determined primarily by duration of hospitalization.

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

Practice guidelines for the management of asthma in children universally recommend systemic corticosteroids for the treatment of moderate to severe asthma exacerbations. However, these guidelines vary widely with respect to dose, frequency, method of delivery, and duration of therapy. In actual practice, there is also considerable variation among clinicians in terms of corticosteroid dosing in children hospitalized with asthma exacerbations. At the Children's Hospital of Philadelphia (CHOP) the current standard is to use an initial dose of 4.0 mg/kg/day (1.0 mg/kg every 6 hours to a maximum of 30 mg/dose) although many other pediatric hospitals use a 2.0 mg/kg/day dose (1.0 mg/kg every 12 hours to a maximum of 30 mg/dose). Systematic reviews of the literature have called for a clinical trial to evaluate the effect of different doses of corticosteroids in treating pediatric asthma patients hospitalized with exacerbations.

This study will use a randomized, double-blind, controlled trial design in order to compare the efficacy of two different steroid doses in resolving acute exacerbations of asthma in hospitalized children. Children being hospitalized for asthma exacerbations from the CHOP emergency department (ED) will be eligible for study enrollment. Those that meet enrollment criteria will be randomized to receive prednisolone either in the higher dose (1.0 mg/kg (max 30 mg) every 6 hours), or the lower dose (1.0 mg/kg (max 30 mg) every 12 hours and placebo doses at 6 hour intervals in between) for the first 48 hours of hospitalization. Once 48 hours has past, all patients still hospitalized will receive 1.0 mg/kg (max 30 mg) every 12 hours for the duration of hospitalization. Approximately 156 patients with 78 in each arm of the study will be enrolled. This study should be completed in six to eight months. A non-inferiority study design will be used. The primary outcome will be duration of hospitalization, as determined by duration of time elapsed from first dose of prednisolone administered in the emergency department (ED) until the discharge dose of albuterol is administered. Secondary outcomes will include time elapsed from the time the admission order is written until the discharge order is written, time spent in each severity level of the asthma care pathway, degree and rate of improvement in forced expiratory volume in one second (FEV1), improvement in peak expiratory flows (PEF), improvement in asthma symptom scores, and rate of relapse after discharge.

Tipo de estudio

Intervencionista

Inscripción (Actual)

152

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • The Children's Hospital of Philadelphia

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

2 años a 18 años (Niño, Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Physician-diagnosed asthma with at least two previous visits to ED or primary care provider for asthma care
  • Clinical decision by ED attending physician to admit to Acute Care Unit (ACU) after standardized initial ED treatment

Exclusion Criteria:

  • Clinical decision to begin continuous intravenous beta-agonist infusion
  • Clinical decision to begin intravenous methylprednisolone therapy
  • Clinical decision to admit to the Pediatric Intensive Care Unit
  • Other concurrent disease such as sickle cell disease, cystic fibrosis, or cardiac disease
  • Any contraindication to corticosteroid administration
  • Any systemic corticosteroid treatment within two weeks of presenting to the ED
  • Potential subjects will be excluded if informed consent is not obtained

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: 1
High dose prednisolone
4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
Otros nombres:
  • corticoesteroides
  • High Dose Prednisolone
  • Oral steriod
  • asthma exacerbations
Experimental: 2
Lower dose prednisolone alternating with placebo
2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
Otros nombres:
  • corticoesteroides
  • Oral steriod
  • asthma exacerbations
  • Low dose Prednisolone
  • Oral prednisolone

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Time Measured From the Administration of the Loading Dose of Prednisolone (2mg/kg up to Max 60mg) in the Emergency Department (ED) Until the Home Dose of Albuterol is Administered
Periodo de tiempo: Median time from loading dose to home dose of albuterol
Median time from loading dose to home dose of albuterol

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Time Measured From the Writing of the Admission Order Until the Writing of the Discharge Order
Periodo de tiempo: Mean time from writing admit order until discharge order
Mean time from writing admit order until discharge order
Time Spent in Each Severity Level of the Asthma Care Pathway
Periodo de tiempo: Time spent in each severity level of pathway
Time spent in each severity level of pathway
The Rate and Degree of Change in Forced Expiratory Volume (FEV1) and Peak Expiratory Flow (PEF) Between Treatment Groups
Periodo de tiempo: Every 4 hours during hospitalization
Every 4 hours during hospitalization
Differences in Clinical Asthma Symptom Scores During Hospitalization Between Treatment Groups
Periodo de tiempo: Every 4 hours during hospitalization
Every 4 hours during hospitalization
Rate of Relapse Between Treatment Groups
Periodo de tiempo: 2 weeks after hospitalization
2 weeks after hospitalization

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Joseph J Zorc, MD, Children's Hospital of Philadelphia

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de febrero de 2006

Finalización primaria (Actual)

1 de noviembre de 2006

Finalización del estudio (Actual)

1 de noviembre de 2006

Fechas de registro del estudio

Enviado por primera vez

22 de noviembre de 2005

Primero enviado que cumplió con los criterios de control de calidad

22 de noviembre de 2005

Publicado por primera vez (Estimar)

24 de noviembre de 2005

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

31 de diciembre de 2010

Última actualización enviada que cumplió con los criterios de control de calidad

23 de diciembre de 2010

Última verificación

1 de diciembre de 2010

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Prednisolone high dose

3
Suscribir